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Abstract: There is an epidemic of obesity starting about 1980 in both developed and
undeveloped countries definitely associated with multiple etiologies. About 670 million
people worldwide are obese. The incidence of obesity has increased in all age groups,
including children. Obesity causes numerous diseases and the interaction between
genetic, metabolic, social, cultural and environmental factors are possible cofactors for the
development of obesity. Evidence emerging over the last 20 years supports the hypothesis
that viral infections may be associated with obesity in animals and humans. The most widely
studied infectious agent possibly linked to obesity is adenovirus 36 (Adv36). Adv36 causes
obesity in animals. In humans, Adv36 associates with obesity both in adults and children and
the prevalence of Adv36 increases in relation to the body mass index. In vivo and in vitro
studies have shown that the viral E4orf1 protein (early region 4 open reading frame 1, Adv)
mediates the Adv36 effect including its adipogenic potential. The Adv36 infection should
therefore be considered as a possible risk factor for obesity and could be a potential new
therapeutic target in addition to an original way to understand the worldwide rise of the
epidemic of obesity. Here, the data indicating a possible link between viral infection and
obesity with a particular emphasis to the Adv36 will be reviewed.
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1. Introduction
Obesity is a disease characterized by an excess of fat mass. The incidence of obesity in recent decades
has grown dramatically [1].
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The prevalence of obesity doubled in adults and tripled in children during the last 20 years, even in
countries with traditionally low rate of the disease. In 2014, more than 1.9 billion adults, 18 years old
and older, were overweight. Of these, over 600 million were obese. The worldwide prevalence of obesity
more than doubled between 1980 and 2014. (World Health Organization (WHO) data; [2]). The risks
of diabetes, hypertension and dyslipidaemia increase starting from a body mass index (BMI) of about
21.0 kg/m2, thereby reducing life expectancy and greatly increasing the health and social economic
burden. Obesity is clearly related to increased mortality, morbidity and disability rates. Overweight
and obesity are the fifth leading risk for global deaths. Obesity is now described as a phenomenon in
character epidemic [3], and according to the WHO, obesity represents “one of the major Public Health
problems of our time”. Obesity is also a risk factor for numerous chronic diseases such as cardiovascular
diseases and diabetes, orthopedic problems and mental disorders. The scientific community started to
study the obesity epidemic looking at the possible causes with the aim to find effective treatments to
reduce morbidity and mortality.
Although obesity is a multifactorial disease caused by the interaction between genetics, metabolism,
social, cultural and environmental factors, viral infection has been suggested as a possible cofactor for
the development of obesity [4].
Immune response depends by nutritional status and can be easily dysregulated in states of imbalanced
nutrition such as obesity. This may predispose obese individuals to increased susceptibility to
infection [5,6].
In the hospital setting, obese patients are more likely to develop secondary infections and
complications such as sepsis, pneumonia, bacteremia, wound infections, and respiratory infections [7,8].
Obesity has been associated with increased risk of complications due to surgical site infections [9–11].
Obese individuals have increased risk of Helicobacter pylori [12] infection and overweight children
show a three times greater risk of Neisseria meningitides [13]. Obesity is also a risk factor of severe
infection and death caused by the pandemic influenza strain H1N1 [14].
Overall, these observations indicate that excessive adipose tissue expansion predisposes individuals
to various infections. On the other hand, new data have been generated in the last few years suggesting
infectious agents being the cause of obesity in addition to being more easily hosted in an obese individual.
Among the multitude of infectious agents, adenoviruses are the human pathogens that more than others
are causatively and correlatively linked with animal and human obesity, respectively, and seem to directly
influence the adipose tissue [15,16].
In animals, adenovirus serotype Adv31 and Adv9 correlate with obesity and are adipogenic in animal
cells culture [17,18]. An avian adenovirus (SMAM-1) and the human adenovirus type 36 (Adv36) have
been associated with obesity [19] and there are reports a suggesting significant role of adenoviruses in
the development of human obesity.
Here we provide an overview of the data available on the relationship between adenovirus infection
and obesity.
2. Association of Viral Infections with Obesity in Animal Models
Five infectious agents were implicated in contributing to obesity, including canine distemper virus
(CDV), rous associated virus (RAV)-7, borna disease virus (BDV) and adenoviruses [19]. Apart from
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adenoviruses, all the other viruses of this list are associated with brain damage and, in experimental
animals, obesity develops via brain involvement or via direct damage of fat tissue. CDV is a
paramyxovirus that infects dogs and other wild mammals; it was one of the first infectious agents
identified to cause enlarged fat cells and increased body weight in mice [19]. The CDV infected animals
showed twofold increase in body weight and a selective, virus-induced disruption of critical brain
catecholamine pathways [20]. RAV-7 is one of the most common retroviruses affecting chickens [21].
The infected chickens are smaller than hatchmates and develop obesity, ataxia, lymphoblastoid
infiltration of thyroid and pancreas, liver fat accumulation and a frank lipemia. BDV is a nonsegmented
negative-stranded RNA virus that may cause obesity in various animals, including rats and chickens.
Most studies suggest that BDV causes obesity by inflammation of the hypothalamus. In infected animals,
hyperplasia of pancreatic islets, increase in glucose and triglyceride levels is also seen [19].
Adenoviruses are the only infective agents reported to be linked with adiposity in both experimental
animal models and naturally infected humans [22].
3. Adenoviruses
Adenoviruses are medium size viruses. All human adenoviral genomes have the same general
organization. The genome consists of a single linear, double-stranded DNA molecule with short inverted
terminal repeats at each end. A protein, terminal protein, is covalently attached to both the 51 ends of
the genomic DNA. The viral chromosome has five early transcription units (E1A, E1B, E2, E3 and E4)
(Figure 1).
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Figure 1. Genomic organization of Adv36: The early proteins (E1A, E1B, E2A, E2B, E3,
and E4) are involved in the regulation of replication of DNA. The late proteins (L1–L5),
products of the translation of late mRNA, constitute structural capsid proteins.
r r r t 50 immunologically distinct serotypes of adenovirus that can cause infections
in humans. Serotypes are operationally defined by the ability of the antibodies induced by infection
to neutralize that serotype only, and not other adenovirus. The human adenoviruses f rt r
l ssified into six subgroups ( –F) based upon he oagglutination proprieties and genetic relatednes .
Although the epidemiological characteristics of the adenovirus serotype change, all are transmitted
by direct contact, fecal-oral transmission, and sometimes by environmental transmission (contaminated
water). Most of the adenovirus cause respiratory diseases, but can also cause gastroenteritis,
conjunctivitis and cystitis [19,23].
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The adenovirus virion contains a 36 kb genome of double-stranded DNA, which is surrounded by a
non-enveloped icosahedral protein capsid. The capsid is composed of 252 capsomers: 240 hexons and
12 pentons at the vertices of the icosahedrons. Each penton consists of a penton base and a penton fiber.
The fibers consist of a slender shaft with a globular head. They are involved in the process of attachment
of the virus particle to the host cell.
Adv2 and Adv5 have been used for most studies of the adenovirus replication cycle. These viruses
can be easily grown in the laboratory by infecting permissive cell lines such as HeLa and A549 cells.
Adv5 and Adv37 increase adiposity in animals and have been indicated as possible contributing
factors to the rising problem of obesity [24], whereas human adenoviruses Adv2 and Adv31 are not
adipogenic in animals. Among the over 50 human adenoviruses available, Adv36 is the most studied also
because of its minimal cross-reactivity with other human adenoviruses [25–27]. The exact mechanisms
leading to the development of obesity through these viruses are unknown. An accurate understanding of
the varied etiological factors of obesity (including infecting agents) may lead to cause-specific treatment
and successful management of this disease.
4. Adv36 and Obesity
4.1. In Vivo Studies
The adipogenic effect of adenoviruses has been studied since 1990, when the adipogenic role of the
avian adenovirus SMAM-1 in chickens was observed for the first time [28]. SMAM-1 is antigenically
similar to chicken embryo lethal orphan virus (CELO), which is common among poultry in the USA.
SMAM-1 increases adiposity in experimentally infected chickens and their naive cage-mates, suggesting
horizontal transmission of obesity induced by the virus [28]. Paradoxically, SMAM-1-induced adiposity
in animals is associated with lower serum cholesterol and triglyceride concentrations compared to
uninfected counterparts [29].
The human adenoviruses Adv5 and Adv37 increase the adiposity in animals, while other
human adenoviruses like Adv2 and Adv31 are not adipogenic [30,31]. Adv36 is adipogenic in
animals [30,32–34] and reduces significantly the concentrations of cholesterol and triglycerides
compared to uninfected controls. Longitudinal studies in monkeys [33] showed a 15%–30% increase
of body weight and a reduction of serum cholesterol after natural infection with Adv36. Adv36 is easily
transmitted between animals [35]. After transfusion of a small amount of blood from Adv36 infected
chicken to another animal, sharing the same cage, the animals became obese [35].
Pasarica et al. [34] showed that rats infected with Adv36 had an increase of weight, insulin sensitivity
and glucose uptake. Furthermore, Adv36 infected non-human primates [33], had increase of weight and
anti-Adv36 antibodies, but a decrease of total cholesterol. Similar results were obtained in marmosets
and a decrease of total cholesterol was found in hamsters [36].
Rats inoculated with Adv36 or UV-inactivated Adv36 [37], showed 23% greater epididymal
fat pad and viral mRNA and DNA were detected in liver, brain and adipose tissue. Either
intranasal or intra-peritoneal routes of viral inoculation showed similar results. Adv36 stimulates
preadipocyte differentiation [38] and CCAAT/enhancer-binding protein beta (C/EBPβ) expression [39].
Pasarica et al. [34] found that Adv36 up-regulated (C/EBPβ) the downstream genes CCAAT/
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enhancer-binding protein alfa (C/EBPα) and glycerol-3-phosphate dehydrogenase (GPDH) in infected
rats, suggesting that the target of Adv36 may be C/EBPβ or genes upstream in the pathway.
Adipogenesis is accelerated by progression of adipocyte proliferation and differentiation, and ultimately,
cellular signaling pathways are affected [38,40]. The expression of early, intermediate, and later genes
of differentiation (such as C/EBPβ) increases, followed by expression of C/EBPα and PPARγ and
lipid accumulation [41]. Particularly, increases in C/EBPβ and PPARγ genes and RNA expressions
related with adipogenesis [42]. These results offer further support to the up-regulation of preadipocyte
differentiation as a mechanism for the adipogenic effect of Adv36.
4.2. In Vitro Studies
The infection with Adv36 accelerates differentiation and proliferation of the 3T3-L1 human
preadipocytes into adipocytes [27,43,44] and increases the concentration of lipid content in fat cells.
In vitro experiments on human stem cells derived from primary adipose tissue/stromal cells (hASC)
support the hypothesis that natural infection with Adv36 in hASC cell line increases adiposity. The
ability to Adv36 to induce adipogenesis in this cell line can provide additional tools to investigate
pathways still unknown [44]. Wang et al. suggest that the dual effects of Adv36 on lipid metabolism
by reducing fatty acid oxidation and increasing de novo lipogenesis, result in fat accumulation in
muscle cells that may be mediated by promoting cell death-inducing DFFA-like effector c/FSP27
expression [45]. Further research to explore the adipogenic potential of human adenoviruses is warranted.
5. Prevalence of Adv36 in Human Obesity
Six human adenoviruses have been studied in relation to obesity [29–31,43] and a number of human
studies have shown a correlation between antibodies to the Adv36 and obesity (Table 1). Due to the
unique amino acid sequences in protruding region of the hexon (loops 1 and 2) of Adv36 [46] there
is a low cross-reactivity between Adv36 and other adenovirus in classical serum neutralization assays
thus, the information derived from these studies are reliable. Furthermore, the Adv36 genome has a high
stability, which is useful for diagnostic purposes and in the development and application of vaccines
and therapeutic reagents [47]. Moreover, bioinformatics comparisons with other human adenoviruses
identified significant differences, suggesting unique functions of Adv36 possibly linking Adv36 with
adipose tissue [40]. In humans, the natural infection with Adv36 is diagnosed by the presence of the
viral DNA in adipose tissue [44,48] or by neutralizing antibodies [49].
Analogously to animals, seropositivity to Adv36 is associated with low level of cholesterol and low
triglyceride concentrations in serum of obese individuals [30].
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Table 1. Studies on the association of Adv36 and obesity. BMI, body mass index; TG, triglycerides; TC, total cholesterol; LDL, low
density lipoprotein; HDL, high density lipoprotein; BG, blood glucose; NAFLD, Nonalcoholic fatty liver disease; SBP, systolic blood
pressure; WC, waist circumstance; NA, not available; SNA, serum neutralization assay; DXA, dual-energy X-ray absorptiometry; VEGF,
vascular endothelial growth factor; MCP-1, monocyte chemoattractant protein-1; TNFα, tumor-necrosis-factor-alpha; IL-6, interleukin-6;
HERITAGE, HEalth, RIsk factors, exercise Training And Genetics; PBRC, Pennington Biomedical Research Center; MET, Mechanisms
of the Metabolic Syndrome in Prepubertal Youth.
First Author Country Parameters BMI Subjects Prevalence of Adv36 Method
Atkinson,
2005 [49]
USA Obesity, BMI, TG, TC BMI ě 30 360 obese and 142 non-obese adults Obese 30% Non-obese 11% SNA
Atkinson,
2005 [49]
USA BMI, TG, TC NA 28 sets of twins Overall 22% SNA
Trovato,
2009 [95]
ITALY
Obesity, BMI, TG, TC,
LDL,HDL, SBP
BMI ě 30 68 obese and 135non-obese adults Obese 65% Non-obese 33% SNA
Atkinson,
2010 [56]
South
Korea
TC, WC, SBP, BG NA
83 obese or overweightchildren and one
nonobese child
Overall 30% SNA
Broderick,
2010 [50]
USA Obesity BMI ě 29 146 obese and 147 non-obese adults Obese 34% Non-obese 39% SNA
Gabbert,
2010 [58]
USA Obesity, BMI, WC
BMI.95
thpercentile
67 obese and 57 non obese children Obese 22% Non-obese 7% SNA
Na, 2010 [53]
South
Corea
Obesity, BMI, TG, TC,
WC,LDL, HDL, SBP, BG
BMI ě 30 259 obese and 59 nonobese children Obese 29% Non-obese 14% SNA
Trovato,
2010 [96]
ITALY BMI, TG, TC, LDL, HDL, BG NA 65 NAFLD and 114 non-NAFLD adults NAFLD 32% Non-NAFLD 46% SNA
(1) HERITAGE Family Study (n 671)
(1) HERITAGE Family Study
13%
(2) PBRC Study (n 206) (2) PBRC Study 18%
(3) MET Study (n 45) (3) MET Study 22%
Krishnapuram,
2011 [97] USA
Fasting insulin, Fasting
glucose, Insulin sensitivity,
HOMA,
NA
(4) VIVA LA FAMILIA Study (n 585)
(4) VIVA LA FAMILIA Study
7.1%
SNA
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Table 1. Cont.
First Author Country Parameters BMI Subjects Prevalence of Adv36 Method
Goossens,
2011 [51]
Netherlands Obesity, BMI NA
136 obese, 281 nonobese, and
92 BMI-unknown adults
5.5% were positive for Adv36
antibodies, No adenoviral
DNA
SNA,
PCR
Na, 2012 [98] South Korea
Obesity, BMI, TG, TC,
WC, HDL, SBP, BG
BMI ě 25 180 obese and 360 non-obese
adults
Obese 30% Non-obese36%
Trovato, 2012 [99] ITALY
BMI, TG, TC, LDL, HDL,
BG
NA 62 NAFLD adults Overall 40% SNA
Almgren, 2012 [54] Sweden
Obesity, BMI, TG, TC,
LDL, HDL, BG
BMI ě 35; 28 ě
BMI ď 25; BMI
< 25
424 children and 1522
nondiabetic adults, and 89
anonymous blood donors
7% in 1992–1998 to 15%–20%
in 2002–2009, increase in
obesity prevalence
SNA and
ELISA
Aldhoon-Hainerova,
2014 [55]
Czech
Republic
anthropometric (body
weight, height, BMI, WC,
fat mass), blood pressure,
biochemical and hormonal
(lipid profile, glucose,
insulin, liver enzymes,
adiponectin)
NA
1179 Czech adolescents (85
underweight, 506 normal
weight, 160 overweight and
428 obese)
26.5% were positive for Adv36
antibodies (underweight:
22.3%; normal weight: 21.5%;
overweight: 40.0% and obese:
28.0%)
ELISA
Vander Wal,
2013 [61]
USA BMI, TC, HDL, LDL, TG
Mean BMI
33.77
73 youth aged 10–17 years
17 youth (23.3%; 2 boys, 15
girls) tested Ad-36 AB+ and
56 youth (76.6%; 14 boys, 42
girls) tested Ad-36 AB´.
SNA
Lin, 2013 [100] MEXICO
Age, sex, Body FAT, BMI,
Fasting glucose, Fasting
insulin
Mean BMI
29.15
1,400 enrolled in the San
Antonio Family Heart Study
Seropositive subjects (14.5%)
had greater adiposity at
baseline, compared with
seronegative subjects.
SNA
Laing, 2013 [101] USA DXA 21 ě BMI ď 24 115 females aged 18 to 19
years
52% and 64% in normal-fat
and high-fat groups
ELISA
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Table 1. Cont.
First Author Country Parameters BMI Subjects Prevalence of Adv36 Method
Vander Wal,
2013 [61]
USA
TC, HDL, LDL,
TG
Mean BMI 37.77 73 youth aged 10-17 years
17 youth (23.3%; 2 boys, 15 girls)
tested Ad-36 AB+ and 56 youth (76.6%;
14 boys, 42 girls) tested Ad-36 AB–
SNA
Parra-Rojas,
2013 [59]
MEXICO
LDL, HDL, TG,
Insulin, Fasting
glucose, HOMA
NA
75 children with normal-weight
and 82 with obesity
Seroprevalence was 73.9%. Ad-36
seropositivity had a higher prevalence in
obese children than in normal weight
group 58.6 versus 41.4%
ELISA
Berger,
2014 [102]
USA
TNF-α, IL-6,
VEGF, MCP-1,
DXA.
20 ě BMI ď 21 291 children aged 9-13 years (50%
female, 49% black)
seropositivity [Ad36(+)] was 42% ELISA
Voss,
2014 [103]
USA NA 20–30 kg/m(2) 500 young, 18–22 years seropositivity [Ad36(+)] was 20.8% ELISA
Karamese,
2015 [104]
Turkey
TG, TC, LDL,
TNF-α, IL-6,
leptin
NA 146 children and 130 adults
27.1% and 6% in obese and non-obese
children and 17.5% and 4% in obese
and non-obese adults
ELISA
Ergin,
2015 [105]
Turkey TC, TG, leptin
Obese BMI > 30;
non-obese adults
with BMI < 25
49 obese adults and 49 non-obese
adults
seroprevalence was 12.2%, DNA was
not detected
SNA,
ELISA,
PCR
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Adv36 DNA has been isolated in few cases. Salehian et al. [48] described a patient with massive fat
deposits in the thorax and abdomen arguing that the abnormal adipose tissue deposits might be caused
by Adv36. Although this case seems in agreement with the increase of adipose tissue found in animals
experimentally infected with Adv36, further studies are needed to understand the actual role of Adv36
in abnormal deposits and fat/lipomatosis in humans [48].
The association of natural Adv36 infection with obesity both in adults and children has been described
(Table 1).
The first study of Ad36 infection in adult humans in the United States showed that about 30% of
obese and 11% of non-obese had been infected, and there was a strong correlation of obesity with
infection [49]. Other studies have confirmed these results (Table 1). The first study of Ad36 infection
in adult humans in the United States showed that about 30% of obese and 11% of non-obese had
been infected, and there was a strong correlation of obesity with infection [42]. Other studies have
confirmed these results (Table 1), while few studies did not confirm this finding [50–52]. The average
Adv36 prevalence ranged from 65% in Italy down to 6% in Belgium/Holland (Table 1). The Adv36
prevalence reported in obese children and non-obese children is 28% and 18%, respectively [53–61].
Two meta-analyses explored the association between Adv36 infection and obesity development. The
first selected 10 studies. The authors found that Adv36 infection associates with the risk of obesity, but
was not associated with abnormal metabolic markers including waist circumstance suggesting that the
infection is more associated with accumulation of subcutaneous fat than that of visceral fat [62].
The second meta-analysis included 11 case-control studies, including 2508 obese subjects and 3005
control. The study identified an association between Ad36 infection and a significantly increased risk of
obesity development, especially in children [63].
6. Molecular and Cellular Mechanisms Involved in Ad-36-Induced Glucose Uptake
Evidence emerging from animal and human studies suggests that some forms of obesity may actually
lead to healthy obesity [24]. Several studies identified one Adv36 gene that mediates glucose disposal
through the Ras/PI3K pathway to improve glucose uptake [64]. The glucose uptake increase may
contribute to the improved glycemic control found in Adv36-infected animals [34].
In vitro, Adv36 induced adipogenic accumulation commitment, differentiation of adipocytes and
increases the cellular glucose uptake [27,44].
In a work by Wang et al. [64], the authors showed that the infection with Adv36 increases glucose
uptake, confirming previous data. In vitro experiments on Human Skeletal Muscle (HSKM) cells showed
an increase of GLUT1 and GLUT4 gene expression mediated by Ras-activated PI 3-kinase pathway
independent from insulin activation (Figure 2).
Considering the crucial role of skeletal muscle in glucose disposal, the ability to modulate its capacity
to uptake glucose may have a major impact on systemic glycemic control. The property of Adv36 to
improve skeletal muscle glucose uptake in an insulin-signaling independent manner is of great potential
interest for the development of new drug targets in insulin resistance diabetes. Subsequently, many
studies have focused on the virus E4orf1 gene that up-regulates the PI3K pathway (Figure 2) [42]. The
E4orf1 gene is transcribed from the first open reading frame of the early gene of Adv36 and produces
a 17 kDa protein (Figure 1) [42]. Adv36 increases cellular glucose uptake via Ras-mediated activation
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of the phosphatidyl inositol 3-kinase (PI3K), and improves hyperglycemia in mice, without reducing
adiposity [65]. In vitro experiments showed that Adv36 significantly increases the absorption of glucose
into 3T3-L1 preadipocytes and identified that the E4orf1 is “sufficient” to up-regulate the absorption
of glucose [26]. The 3T3-L1 cell line expressing E4orf1 had an increased glucose uptake compared to
null vector control cells. Moreover, E4orf1 up-regulated PI3K pathway and increased the Ras-molecule
required to stimulates the Adv36-induced glucose uptake. Glucose uptake increases significantly in
preadipocytes, adipocytes, or myoblasts derived from 3T3-L1 cells transiently transfected with E4orf1.
Thus, the attractive anti-hyperglycemic effect of Adv36 could be mediated by the E4orf1 protein, which
may offer a novel ligand to develop hypoglycemic drugs. Cellular uptake of glucose can be improved
by up-regulation of Ras signaling in either insulin-dependent or insulin-independent diabetes. In the
presence of an intact insulin signal, Ras plays a negligible role in glucose uptake. On the contrary, when
the insulin signal is reduced like in obesity or diabetes, the insulin-independent Ras pathway can be
useful to improve the glucose disposal. Adv36 increases cellular uptake of glucose by upregulating the
Ras/Glut4pathway (Figure 2). These data improved the knowledge on the role of E4orf1 as a mediator
of Adv36-induced glucose uptake [26].
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secretory protein, and therefore does not have a cell surface receptor for cell entry. Thus, E4orf1 provides
a valuable model to exogenously modulate hepatic glucose and lipid metabolism [66].
In summary, Adv36 may serve two different purposes, on the one hand, to explain the
pathophysiology of certain cases of obesity and, on the other hand, to provide a potential weapon for
improving insulin resistance, regardless of the consumption of fat.
Collectively, these results can provide a model to develop new agents for the treatment of
hyperglycemia associated with obesity, and type 1 or type 2 diabetes [25]. Although the in vivo efficacy
and safety of E4orf1 in improving hyperglycemia remain unknown, and an appropriate drug delivery
system is required, Adv36 E4orf1 offers a research opportunity to develop new anti-diabetic agents
with new conceptually advances for the use of a rather unconventional source, viral proteins, in the
anti-diabetic drug development [25].
7. Adenovirus 36 and Immune Response
7.1. Inflammation: MCP-1 (Macrophage Chemoattractant Protein I) and Adv36
Obese subjects have altered the overall number of circulating T-cells and obesity has been associated
with decreased thymic output of naive T-cells [67–69]. When analyzed by flow cytometry, decreased
CD8 T-cell populations and increased or decreased numbers of CD4 T-cells compared with lean
controls are found [70]. The inflammatory network in obesity may present different immunologic
phenotypes depending on the degree of metabolic disorder. In lean individuals, adipose tissue is mainly
characterized by anti-inflammatory condition, while obesity shifts towards a pro-inflammatory status.
Obesity negatively impacts the ability of dendritic cells (DCs) to mature and elicit appropriate T-cell
responses to a general stimulus. This may contribute to the increased susceptibility to viral infection
observed in severe obesity [71]. Adv36 infection could induce obesity through inflammation, and
MCP-1 may be a key regulator of adenovirus 36-induced obesity in Adv36-infected mice [72]. Thus,
Adv36 could cause chronic inflammation by increasing the levels of MCP-1, activating nuclear factor κB
(NF-κB), inducing the infiltration of macrophages into adipocytes, and altering lipid metabolism [72].
The correlation between obesity and inflammation has been known for decades from epidemiological
and cellular studies [73,74]. Hypertrophic adipocytes may produce pro-inflammatory cytokines such
as MCP-1, TNF-α, resistin, and plasminogen activator inhibitor-1 [75,76]. It was previously found
that Adv36 infection triggers the inflammatory pathway in human mesenchymal stem cells, which was
confirmed by microarray analysis [77].
It has been reported that MCP-1 is responsible for obesity, insulin resistance, and steatosis in
MCP-1 transgenic mice and obese mice [78] and inhibition of MCP-1 ameliorates insulin resistance
and hepatic steatosis [78]. MCP-1 plays a role in the recruitment of monocytes and macrophages
into adipose tissue [78,79] and TNF-α increases the number of macrophages in adipose tissue [80,81].
Macrophages upregulate production of the anti-inflammatory cytokine IL-10 and downregulate synthesis
of pro-inflammatory cytokines. Functionally, there are macrophages that are associated with the repair
of injured tissues and the resolution of inflammation. So, it has been shown that the macrophages
accumulate in the adipose tissues of obese mice mainly expressing genes associated with an M1 or
“classically activated” macrophage phenotype, whereas adipose tissue macrophages from lean mice
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express genes associated with an M2 or “alternatively activated” macrophage phenotype [82]. Adv36
infection increased M1 macrophages migration into adipocytes by activating nuclear factor κB (NFkB),
which induced the release of pro-inflammatory citokynes. In the study of Na et al. [77] on in vivo
experimental infection in mice, Adv36 infection stimulates an inflammatory state due to the increased
level of MCP-1 through the activation of NFkB, which in turn induces the infiltration of macrophages into
adipocytes. Adv36 infection increases MCP-1, and MCP-1 might function to induce adipogenesis via
MCP-1-related factors in adipocytes. Furthermore, increased MCP-1 triggers macrophage infiltration
into adipocytes and inflammation may play a role in maintaining obesity [72]. Therefore, on the
basis of these data, we could assume that there is a relationship between Adv36-induced obesity
and inflammation.
7.2. Effect of Adv36 on Leptin
Conventionally, obesity can be considered an over accumulation of white adipose tissue (WAT).
Although adipocytes occupy the bulk of the volume of WAT, adipose tissue also includes many more cells
types, including a diverse population of preadipocytes, macrophages, endothelial cells, fibroblasts and
leukocytes [83]. Adipose tissue, traditionally thought as a passive storage for triglycerides and energy,
but in the past two decades it has been linked to the production of several hormones, pro-inflammatory
chemokines, adipokines and cytokines, including leptin, adiponectin, resistin, visfatin, B-cell activating
factor of the Tumor Necrosis Factor (TNF) family, TNF-like weak inducer of apoptosis, a proliferation
inducing ligand, TNF-α, omentin and MCP-1 [5]. Based on this concept, adipose tissue has been defined
an endocrine organ. In the obese state, secretion of these adipokines is altered in correlation to the
increased adipose tissue mass [84,85]. To date, adipokine modulation of immune function by leptin is
the best-characterized link between obesity and immune function. Leptin plays a role in many diverse
physiological processes but is primarily involved in energy homeostasis and satiety [86,87].
Leptin acts as a general signal of energy reserves and modulates food intake. Leptin levels
increase proportionately to adipose mass resulting in high circulating leptin concentrations in obese
individuals [88,89].
The leptin receptor is expressed by B and T lymphocytes and may directly modulate the T and B
responses [90]. Leptin seems to exert its effects on immune cells through the JAK /STAT pathway.
In peripheral blood mononuclear cells, leptin increases JAK2/3 and STAT3 phosphorylation, which
promote proliferation and activation of T lymphocytes upon mitogen stimulation. In terms of infectious
disease, the general consensus seems to be that leptin has an anti-inflammatory role, while at the
same time serving a protective capacity against infections [91]. Inflammation is used as a localized,
protective response to infection and changes in body weight and metabolic state are often associated
with acute or chronic inflammatory processes resulting from infection [38]. The inhibition of leptin gene
expression by Adv36 infection may increase lipid accumulation and obesity prevalence reported that
human cells infected with Adv36 showed greater differentiation and higher levels of lipid accumulation
than non-infected control cells [43] (Figure 3). Adv36 infection may increase appetite and food intake
by decreasing norepinephrine levels and leptin [92], thereby increasing obesity prevalence (Figure 4).
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8. Proof-of-Concept of a Vaccine Using UV Inactivated Adv36
Adv36 infection is characterized by greater adiposity and inflammation. To investigate the possibility
that a candidate prophylactic vaccine could protect Adv36-induced obesity and inflammation an
inactivated Adv36 vaccine was tested [37]. Mice were inoculated with live Adv36, UV-inactivated
Adv36, or with medium alone. Live Adv36 increased the size of the epididymal fat pad at four days
post-inoculation, whereas UV-inactivated Adv36 prevented it. In another study, mice were immunized
with purified and ultraviolet-irradiated virus as candidate vaccine, live Adv36 was injected into mice as a
challenge test. Unvaccinated mice (control group) were immunized with phosphate-buffered saline and
then challenged with live Adv36. The control group showed 17% greater body weight and 20% more
epididymal fats compared with the vaccinated group. Moreover, the vaccinated group had decreased
serum levels of pro-inflammatory cytokines, and infiltrated immune cells in fat tissue [93]. Therefore,
the vaccine was able to protect against Adv36-increased body weight and fat as well as inflammatory
states after challenge. These results could provide proof-of-concept for prophylactic vaccination against
virus-induced adiposity [94].
9. Conclusions
Obesity is a multifactorial pathology and the understanding of the different contributing factors is
crucial for its efficient management.
Recent studies have shown a possible correlation between obesity and Adv36 viral infections.
Animals infected with Adv36 show increase of body weight and physiological changes, increased
glucose absorption and decreased secretion of leptin and cholesterol (Figure 4).
The Adv36 infections should therefore be considered as a possible risk factor for obesity and this
could be a potential new way to investigate on the worldwide epidemic of obesity. Further research
on viruses contributing to obesity is essential. Studying the favorable effect of Adv36 on metabolic
consequences of obesity may provide insight to novel treatments that improve glycemic control despite
adiposity. Identifying the viral protein responsible for influencing glucose disposal may help in
developing novel anti-diabetic therapeutic agents.
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